US Patent

US12403109 — Sotalol hydrochloride dosing

Method of Use · Assigned to Altathera Pharmaceuticals LLC · Expires 2028-08-14 · 2y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel methods of administering sotalol hydrochloride to patients.

USPTO Abstract

The present invention provides novel methods of administering sotalol hydrochloride to patients in need thereof.

Drugs covered by this patent

sotalol-hydrochloride (SOTALOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2769`	—	sotalol-hydrochloride

Patent Metadata

Patent number: US12403109
Jurisdiction: US
Classification: Method of Use
Expires: 2028-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Altathera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.